Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well arsenic trioxide works in treating patients with
relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy, such as arsenic
trioxide, work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing.